Prescribing information

 

   

Explore our range of useful resources below, designed to support you with your decision making. You can download the files to refer to later.

▼Beovu® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to diabetic macular oedema (DMO).1,2

 

Front cover image of formulary app pack for Beovu in wAMD

Formulary application pack for Beovu® in wAMD

Information intended to support you with your local formulary submission for Beovu; for the treatment of patients with wet age-related macular degeneration (wAMD).

Registration is required to access this resource.

Download resource

Image of Beovu formulary application support pack for Beovu in DMO

Formulary application pack for Beovu® in DMO

Information intended to support you with your local formulary submission for Beovu; for the treatment of patients with visual impairment due to diabetic macular oedema (DMO).

Registration is required to access this resource.

Download resource

 

 

recommended by nice

reviewed by smc

 

Request for budget impact model call

Request a conversation with a Novartis Account Manager to discuss the Beovu budget impact model, which supports an assessment of the impact of Beovu on service capacity and costs.

Request contact

 

Request value proposition call

Request a conversation with a Novartis Account Manager to view the Beovu value proposition, which provides an overview of the clinical, system and service benefits.

Request contact

Image of Beovu logo

If you are also a UK healthcare professional you can click below to view more information on ▼Beovu® (brolucizumab).

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

 

 

AMD, age-related macular degeneration; DMO, diabetic macular oedema; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; wAMD, wet AMD.

Reference

  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. National Institute for Health and Care Excellence (2021) Brolucizumab for treating wet age-related macular degeneration (NICE guideline 672). Available at: https://www.nice.org.uk/guidance/ta672. [Accessed May 2022].
  4. Scottish Medicines Consortium. Available at: https://www.scottishmedicines.org.uk/medicines-advice/brolucizumab-beovu-full-smc2272/ [Accessed May 2022].
Rate this content: 
No votes yet
UK | May 2022 | 208400
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]